Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard H Feldman

Showing results (31-40 of 160) with videos related to

Pageof 16
Sort By:
Neurology|July 20, 2019
Cognitive heterogeneity in probable Alzheimer disease: Clinical and neuropathologic featuresYuqi Qiu, Diane M Jacobs, Karen Messer, et al.
International Journal of Statistics in Medical Research|March 15, 2024
Optimal Weighting of Preclinical Alzheimer's Cognitive Composite (PACC) Scales to Improve their Performance as Outcome Measures for Alzheimer's Disease Clinical TrialsXinran Wang, Diane Jacobs, David P Salmon, et al.
Alzheimer Disease and Associated Disorders|August 28, 2022
Exploring Social Cognition Tests to Differentiate Frontotemporal Dementia from Depression: A Two-Step Pilot StudyMaya L Lichtenstein, Peter V Stewart, H Lester Kirchner, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|April 6, 2006
Progress in clinical neurosciences: Canadian guidelines for the development of antidementia therapies: a conceptual summaryHoward H Feldman, Serge Gauthier, Howard Chertkow, et al.
Frontiers in Medicine|October 24, 2022
Pharmacological thiamine levels as a therapeutic approach in Alzheimer's diseaseGary E Gibson, Howard H Feldman, Sheng Zhang, et al.
Journal of the Neurological Sciences|November 5, 2010
rs5848 polymorphism and serum progranulin levelGing-Yuek R Hsiung, Alice Fok, Howard H Feldman, et al.
Journal of Alzheimer'S Disease : JAD|January 15, 2019
Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by IndicationBranko N Huisa, Ronald G Thomas, Shelia Jin, et al.
Alzheimer'S Research & Therapy|September 29, 2018
Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY)Elizabeth Finger, Scott Berry, Jeffrey Cummings, et al.
American Journal of Alzheimer'S Disease and Other Dementias|January 2, 2008
Clinical presentation of prodromal frontotemporal dementiaBradley J Hallam, Noah D Silverberg, Amanda K Lamarre, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 5, 2024
Developing the Healthy Actions and Lifestyles to Avoid Dementia or <i>Hispanos y el ALTo a la Demencia</i> programSara Moukarzel, Zvinka Z Zlatar, Sheri J Hartman, et al.
Pageof 16

Showing results (31-40 of 160) with videos related to

Sort By:
Pageof 16
Neurology|July 20, 2019
Cognitive heterogeneity in probable Alzheimer disease: Clinical and neuropathologic featuresYuqi Qiu, Diane M Jacobs, Karen Messer, et al.
International Journal of Statistics in Medical Research|March 15, 2024
Optimal Weighting of Preclinical Alzheimer's Cognitive Composite (PACC) Scales to Improve their Performance as Outcome Measures for Alzheimer's Disease Clinical TrialsXinran Wang, Diane Jacobs, David P Salmon, et al.
Alzheimer Disease and Associated Disorders|August 28, 2022
Exploring Social Cognition Tests to Differentiate Frontotemporal Dementia from Depression: A Two-Step Pilot StudyMaya L Lichtenstein, Peter V Stewart, H Lester Kirchner, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|April 6, 2006
Progress in clinical neurosciences: Canadian guidelines for the development of antidementia therapies: a conceptual summaryHoward H Feldman, Serge Gauthier, Howard Chertkow, et al.
Frontiers in Medicine|October 24, 2022
Pharmacological thiamine levels as a therapeutic approach in Alzheimer's diseaseGary E Gibson, Howard H Feldman, Sheng Zhang, et al.
Journal of the Neurological Sciences|November 5, 2010
rs5848 polymorphism and serum progranulin levelGing-Yuek R Hsiung, Alice Fok, Howard H Feldman, et al.
Journal of Alzheimer'S Disease : JAD|January 15, 2019
Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by IndicationBranko N Huisa, Ronald G Thomas, Shelia Jin, et al.
Alzheimer'S Research & Therapy|September 29, 2018
Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY)Elizabeth Finger, Scott Berry, Jeffrey Cummings, et al.
American Journal of Alzheimer'S Disease and Other Dementias|January 2, 2008
Clinical presentation of prodromal frontotemporal dementiaBradley J Hallam, Noah D Silverberg, Amanda K Lamarre, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 5, 2024
Developing the Healthy Actions and Lifestyles to Avoid Dementia or <i>Hispanos y el ALTo a la Demencia</i> programSara Moukarzel, Zvinka Z Zlatar, Sheri J Hartman, et al.
Pageof 16